Published in Int J Cancer on January 24, 2012
3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer. Cancer Manag Res (2013) 0.96
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol (2011) 0.89
Role of phosphoinositide 3-kinase in the pathogenesis of acute pancreatitis. World J Gastroenterol (2014) 0.78
Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther (2014) 0.77
Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. Front Physiol (2014) 0.75
Applying NGS Data to Find Evolutionary Network Biomarkers from the Early and Late Stages of Hepatocellular Carcinoma. Biomed Res Int (2015) 0.75
Platelet-rich plasma stimulates angiogenesis in mice which may promote hair growth. Eur J Med Res (2017) 0.75
Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis. Medicine (Baltimore) (2017) 0.75
Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology (2011) 2.33
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opin Ther Targets (2012) 1.99
Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer (2004) 1.76
The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta (2006) 1.75
Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology (2009) 1.74
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology (2008) 1.73
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell (2007) 1.53
Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol (2005) 1.49
Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. EMBO J (2003) 1.42
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res (2005) 1.38
AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer (2008) 1.37
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene (2002) 1.33
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene (2004) 1.28
Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology (2009) 1.27
Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology (2010) 1.26
Inhibiting TGF-β signaling in hepatocellular carcinoma. Biochim Biophys Acta (2010) 1.20
Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol (2002) 1.17
Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res (2010) 1.15
Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta (2007) 1.14
Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res (2008) 1.14
SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer (2005) 1.11
Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate (2007) 1.08
Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells. J Biol Chem (2010) 1.08
Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C. Intervirology (2010) 1.08
Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II. PLoS One (2013) 1.06
Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer (2002) 1.05
Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res (2003) 1.04
Tetraspanin CD81 is linked to ERK/MAPKinase signaling by Shc in liver tumor cells. Oncogene (2004) 1.04
4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg Med Chem (2008) 1.03
Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines. Blood (2004) 1.02
Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. J Cell Sci (2002) 1.02
Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. Int J Cancer (2005) 1.01
Target therapies in pancreatic carcinoma. Curr Med Chem (2014) 1.01
A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer (2014) 1.01
Age-related impairment of GM-CSF-induced signalling in neutrophils: role of SHP-1 and SOCS proteins. Ageing Res Rev (2006) 1.00
The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol (2003) 1.00
TLRs innate immunereceptors and Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) CIDR1α-driven human polyclonal B-cell activation. Acta Trop (2011) 0.99
Akt/protein kinase B in skeletal muscle physiology and pathology. J Cell Physiol (2011) 0.99
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci (Landmark Ed) (2011) 0.97
Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis. J Cell Physiol (2013) 0.97
Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion. Clin Exp Metastasis (2002) 0.97
3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer. Cancer Manag Res (2013) 0.96
APC-dependent impairment of T cell proliferation in aging: role of CD28- and IL-12/IL-15-mediated signaling. Mech Ageing Dev (2002) 0.96
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. PLoS One (2013) 0.95
Targeting phosphoinositide 3-kinase pathways in pancreatic cancer--from molecular signalling to clinical trials. Anticancer Agents Med Chem (2011) 0.95
Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol (2003) 0.95
Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology (2007) 0.95
Lysophosphatidylinositol signalling: new wine from an old bottle. Biochim Biophys Acta (2012) 0.95
Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatol Res (2002) 0.94
Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer (2014) 0.94
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. Int J Biol Markers (2009) 0.93
Hepatic oxidative alterations in patients with extra-hepatic cholestasis. Effect of surgical drainage. J Hepatol (2002) 0.93
EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol (2008) 0.93
Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem (2007) 0.91
A novel regulatory mechanism links PLCγ1 to PDK1. J Cell Sci (2012) 0.91
Phosphatidylinositol 3-kinase in breast cancer: where from here? Clin Cancer Res (2007) 0.91
Cancer invasion: watch your neighbourhood! Tumori (2003) 0.91
Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci (2013) 0.91
Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol (2006) 0.90
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol (2012) 0.90
Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy. Int J Cancer (2012) 0.89
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol (2011) 0.89
[An unusual case of transient loss of consciousness: the Fahr's syndrome]. Recenti Prog Med (2008) 0.89
Role and regulation of phosphatidylinositol 3-kinase β in platelet integrin α2β1 signaling. Blood (2011) 0.88
Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Mol Cancer (2009) 0.88
Hepatic stellate cells stimulate HCC cell migration via laminin-5 production. Clin Sci (Lond) (2011) 0.88
Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer. Anticancer Res (2013) 0.88
Antifibrogenic effect of IFN-alpha2b on hepatic stellate cell activation by human hepatocytes. J Interferon Cytokine Res (2006) 0.87
HCC heterogeneity: molecular pathogenesis and clinical implications. Cell Oncol (2009) 0.87
655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations. Cell Oncol (2007) 0.87
A phosphoinositide 3-kinase/phospholipase Cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation. PLoS One (2009) 0.86
Gelatinase expression at positive patch test reactions. Contact Dermatitis (2002) 0.86
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem Pharmacol (2005) 0.85